Additional functionality for plecstatin-1-analogous anticancer Ru(η-p-cymene)Cl complexes.
The bioactivity of organometallic compounds can be enhanced by modifying the ligand to achieve higher potency or an altered mode of action.
APA
Iqbal S, Ashraf A, et al. (2026). Additional functionality for plecstatin-1-analogous anticancer Ru(η-p-cymene)Cl complexes.. Journal of inorganic biochemistry, 276, 113168. https://doi.org/10.1016/j.jinorgbio.2025.113168
MLA
Iqbal S, et al.. "Additional functionality for plecstatin-1-analogous anticancer Ru(η-p-cymene)Cl complexes.." Journal of inorganic biochemistry, vol. 276, 2026, pp. 113168.
PMID
41380189
Abstract
The bioactivity of organometallic compounds can be enhanced by modifying the ligand to achieve higher potency or an altered mode of action. Here, we conjugated amino acids to pyridine-2-carbothioamides (PCAs) and formed their Ru(cym)Cl (cym = η-p-cymene) organometallics, as confirmed by mass spectrometry, NMR spectroscopy and elemental analysis. The in vitro antiproliferative activities of ligands 1-4 and complexes 1a-4a were established against human non-small cell lung carcinoma (NCI-H460), cervical carcinoma (SiHA), colorectal carcinoma (HCT116) and colon adenocarcinoma (SW480) cell lines. Complexes 1a-3a showed no activity but 4a was moderately potent with an IC value of 35 μM in NCI-H460 cells. Organoruthenium compound 4a was also more active than its PCA ligand 4 and the clinically investigated Ru complex KP1339 in NCI-H460 cells.
MeSH Terms
Humans; Antineoplastic Agents; Ruthenium; Cell Line, Tumor; Coordination Complexes; Cymenes; Cell Proliferation